Antimicrobial, anticancer and immunomodulatory potential of new quinazolines bearing benzenesulfonamide moiety

Future Med Chem. 2023 Feb;15(3):275-290. doi: 10.4155/fmc-2022-0297. Epub 2023 Mar 9.

Abstract

Sulfonamides are privileged candidates with potent anti-methicillin-resistant Staphylococcus aureus (MRSA) activity and could replenish the MRSA antibiotic pipeline. The initial screening of a series of quinazolinone benzenesulfonamide derivatives 5-18 against multidrug-resistant bacterial and fungal strains revealed their potent activity. The promising compounds were conjugated with ZnONPs to study the effect of nanoparticle formation on the antimicrobial, cytotoxic and immunomodulatory activity. Compounds 5, 11, 16 and 18 revealed promising antimicrobial and cytotoxic activities with superior safety profiles and enhanced activity upon nanoformulation. The immunomodulatory potential of compounds 5, 11, 16 and 18 was assessed. Compounds 5 and 11 demonstrated an increase in spleen and thymus weight and boosted the activation of CD4+ and CD8+ T lymphocytes, confirming their promising antimicrobial, cytotoxic and immunomodulatory activity.

Keywords: MDR; MIC; cytotoxicity; immunomodulatory; quinazoline; sulfonamide.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Infective Agents* / pharmacology
  • Antineoplastic Agents* / pharmacology
  • Benzenesulfonamides
  • Methicillin-Resistant Staphylococcus aureus*
  • Microbial Sensitivity Tests
  • Quinazolines / pharmacology
  • Sulfonamides / pharmacology

Substances

  • Quinazolines
  • Anti-Infective Agents
  • Anti-Bacterial Agents
  • Sulfonamides
  • Antineoplastic Agents